HeyJaredLabiotech.eu
Labiotech.eu is a specialized digital publication focused on the European biotechnology ecosystem, with coverage that blends science, business, and market intelligence.
- Indexed articles, last 90 days
- 15
- Latest publication
- Aug 3, 2026
- Audience
- Top 5M sites
- Earliest in this view
- Jul 3, 2026
Latest articles
10 biotechs in Japan to watch in 2026 (opens the original)
Read excerpt
While Japan historically lacked foreign investment, the field is becoming more dynamic. Discover ten essential biotech companies in Japan. The post 10 biotechs in Japan to watch in 2026 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and
Merck after Keytruda: what the pipeline looks like (opens the original)
Read excerpt
Delve into what Merck has planned for the future of its pipeline as Keytruda's patent is getting closer to expiry. The post Merck after Keytruda: what the pipeline looks like appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.
Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s (opens the original)
Read excerpt
Today we welcome Gene Mack, President and CEO of Gain Therapeutics. Their lead candidate is advancing toward Phase 2 as a potential first-in-class disease-modifying therapy for Parkinson’s disease The post Gain Therapeutics: a first-in-class, disease-modifying therapy for Parkinson’s appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s auth
Meeting unmet needs: new treatments for gout race in the clinic (opens the original)
Read excerpt
About half the people with gout don't have treatments that work for them. New drugs in the clinic could address this underserved population. The post Meeting unmet needs: new treatments for gout race in the clinic appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit
Mouse models and CRO selection critical to de-risking neurology drug development (opens the original)
Read excerpt
CNS drug development lags far behind oncology, but translationally relevant mouse models can help close that gap and improve trial outcomes. The post Mouse models and CRO selection critical to de-risking neurology drug development appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.